Breast Cancer Articles

TNBC Paradigm Evolving With Intriguing Treatment Methods
Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.
CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer
Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.
Prognostic and Predictive Assays Guide Therapy Decisions in Breast Cancer
Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer. 
Cristofanilli Calls for More Effective Options in <em>ESR1</em>-Mutant Breast Cancer
Massimo Cristofanilli, MD, discusses emerging treatment approaches for patients with estrogen receptor-positive/HER2-negative breast cancer with an ESR1 mutation. 
Early Adjuvant Chemotherapy Dose Reductions Correlate With Poorer Survival in Breast Cancer
Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer.
An updated biologics license application has been submitted to the FDA for eflapegrastim for the management of chemotherapy-induced neutropenia.
FDA Recommends Boxed Warning, Additional Labeling Measures for Breast Implants
The FDA has issued a draft guidance to propose labeling recommendations, including a boxed warning, to breast implant manufacturers in an effort to help patients understand the benefits and risks of these devices.
Surgical Pioneer Flips the Script on Early Breast Cancer Treatment
Armando E. Giuliano, MD, a 2018 OncLive Giants of Cancer Care® award winner in Surgical Oncology, disrupted the treatment landscape for early breast cancer when he introduced sentinel lymph node biopsy. The result led to improved quality of life and reduced the need for radical breast cancer procedures for many patients.
Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.
Tracing Treatment Strategies in Early-Stage HR+/HER2- Breast Cancer
Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.
Publication Bottom Border
Border Publication